Navigation Links
Male fertility expert Marvin Meistrich elected AAAS Fellow
Date:2/13/2009

HOUSTON - Illuminating the molecular details of normal sperm development, demonstrating how chemotherapy or radiation can leave a man or boy sterile, and pursuing ways to restore fertility have earned a major honor for a scientist at The University of Texas M. D. Anderson Cancer Center.

Marvin Meistrich, Ph.D., professor in M. D. Anderson's Department of Experimental Radiation Oncology, will be inducted as a fellow of the American Association for the Advancement of Science at the association's annual meeting Saturday, Feb. 14, in Chicago.

"Our goal is to find ways to restore the fertility of the thousands of young men and boys every year who receive treatment that might leave them sterile while curing their disease," Meistrich said.

AAAS, founded in 1848, is the world's largest general scientific society. Meistrich is the eighth AAAS fellow on M. D. Anderson's faculty.

"Addressing quality-of-life issues that arise from surviving cancer is an increasingly important aspect of our research. Recognition of Dr. Meistrich's leadership and innovation in this field is richly deserved," said Raymond DuBois, M.D., Ph.D., M. D. Anderson provost and executive vice president and an AAAS fellow since 2004.

Before undergoing treatment now, men can bank their sperm for later in vitro fertilization. Boys have no options for later reproduction. Chemotherapy and radiation destroy stem cells called spermatagonia that differentiate into sperm. If all the stem cells are destroyed, sterility results.

"An important focus of our research is the possibility of banking these sperm stem cells before treatment and then transplanting them later to launch normal sperm production," Meistrich said. This procedure is done now in mice, and Meistrich's plan is to attempt the same in primates.

Normal sperm production begins with the spermatagonia, which either divide into more stem cells or differentiate into cells called spermatocytes then to spermatids and finally sperm, with the male hormone testosterone crucially involved all along.

A major, surprising discovery by Meistrich and colleagues implicates testosterone in the inability of surviving stem cells to restore sperm production after radiation or chemotherapy.

"This was exactly backwards from what we expected to find," Meistrich said. Rat experiments showed that surviving stem cells could not make the next step in sperm development - differentiation into spermatocytes - because of testosterone's effects on the cells that support and nourish the developing sperm cells.

"So we suppressed testosterone until spermatocytes formed, then restored it to complete the process of sperm development," Meistrich said. While this has worked in rodents, translating it to primates has been more complicated, Meistrich said.

"We are trying to understand the molecular mechanism at work in rodents so we can manipulate that mechanism in primates," he said.

Other major contributions from Meistrich's lab include:

  • Development of methods to separate the different cell types in the sequence of sperm development, or spermatogenesis.
  • Demonstration that X- and Y-chromosome sperm can be distinguished from each other through flow cytometry, which led to sorting of these cells.
  • Collaboration with M. D. Anderson clinical faculty to determine which chemotherapeutic and radiation treatments at what doses cause sterility. The resulting information is used in counseling patients about their reproductive options before treatment.
  • Discovery that cancer therapies produce a five-fold increase in chromosome number mutations in sperm formed during treatment. These mutations, which pose a risk of spontaneous abortion or birth defects if conception occurs during or soon after therapy, return to baseline levels months after treatment. Patients are now counseled about this elevated short-term risk and informed that there is no detectable risk if conception occurs 6 months to a year after therapy.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Wanted: Pioneer IVF Babies Bay Area Fertility Doctors Launch National Search for First IVF Babies Born 25 Years Ago
2. Special Discounts On Fertility Treatment For Active Duty and Retired Military
3. Fertility Expert Calls Birth of Octuplets Criminal
4. Fertility Focused Acupuncture NW & Associates to Open Clinic in Tacoma
5. Fertility Drugs Do Not Increase Ovarian Cancer Risk
6. Household chemicals may be linked to infertility
7. Local Infertility Specialist, Dr. Rachel Bennett, Westchester Reproductive Medicine, Opens New Office in Mount Kisco
8. The AFAs Infertility Prevention Series Premieres in NYC
9. Free Early Education Program to Lower Infertility Rates
10. Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
11. Secondhand smoke raises odds of fertility problems in women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Male fertility expert Marvin Meistrich elected AAAS Fellow
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader ... the position of Executive Vice President, Sales and Marketing. Finnegan is a widely ... medical device sales leadership. He has received industry recognition for innovations and new ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a DAO (decentralized autonomous ... Ethereum blockchain, has released their technical specifications . , 2017 has seen an ... systematic approach for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder ...
(Date:6/27/2017)... Orlando, FL (PRWEB) , ... June 27, 2017 ... ... the leading payment solution for many of the health care industry’s hospitals and ... its new patient financing portal for select customers. Parasail Health is a San ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... AVIV, Israel , June 27, 2017  Therapix ... specialty clinical-stage pharmaceutical company specializing in the development of ... The Nasdaq Stock Market Opening Bell in ... 2017 in honor of its initial public offering (IPO) ... Capital Market in March 2017. Dr. Elran ...
(Date:6/27/2017)... 27, 2017   NuEyes (NuEyes Technologies Inc.) today ... fuel its growth in helping the legally blind live more ... Group), the leading developer of augmented, virtual and mixed reality ... The undisclosed funding amount was provided by strategic partners ... with offices in Abu Dhabi , ...
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 ... that validate the use of MMprofiler with SKY92, the ... myeloma (MM). In a poster presentation at the 22 ... in Madrid, Spain , SkylineDx researchers ... high-risk elderly patients. In a separate ...
Breaking Medicine Technology: